The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia

Dmytro Dmytriiev; Oleksandr Nazarchuk; Yuliana Babina

doi:10.31636/prmd.v4i2.1

Authors

Dmytro Dmytriiev National Pirogov Memorial Medical University, Vinnytsia
Oleksandr Nazarchuk National Pirogov Memorial Medical University, Vinnytsia
Yuliana Babina National Pirogov Memorial Medical University, Vinnytsia

DOI:

https://doi.org/10.31636/prmd.v4i2.1

Keywords:

fluoroquinolones, moxifloxacin, treatment, pneumonia, COVID-19

Abstract

The article presents the results of domestic and international studies of the use of the fourth-generation fluoroquinolone moxifloxacin in the treatment of commu-nity-acquired pneumonia and pneumonia caused by SARS-CoV-2. Analysis of the clinical use of moxifloxacin in the treatment of complications of the respiratory tract infec-tions indicates its high efficiency and bioavailability, a low risk of resistance, which makes it possible to recommend it for widespread use in the work of a practicing doctor. Ge-neric drug Maxicin (Yuria-Pharm), available as a 20 mg/ml concentrate in a 20 ml vial, can significantly reduce the cost of treatment and optimize infusion therapy by choosing both volume and solvent.

Downloads

Download data is not yet available.

References

Wiemken T, Peyrani P, Ramirez J. Global Changes in the Epidemiology of Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine [Internet]. Georg Thieme Verlag KG; 2012 Jun;33(03):213–9. Available from: https://doi.org/10.1055/s-0032-1315633

Polverino E. Community-acquired pneumonia. Minerva anestesiologica. 2011 Jan 18;77(2):196-211.

Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. European Respiratory Journal [Internet]. European Respiratory Society (ERS); 2000 Apr;15(4):757–63. Available from: https://doi.org/10.1034/j.1399-3003.2000.15d21.x

Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax [Internet]. BMJ; 2010 Aug 20;67(1):71–9. Available from: https://doi.org/10.1136/thx.2009.129502

Nair GB, Niederman MS. Community-Acquired Pneumonia: An Unfinished Battle. Medical Clinics of North America [Internet]. Elsevier BV; 2011 Nov;95(6):1143–61. Available from: https://doi.org/10.1016/j.mcna.2011.08.007

Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, et al. The Burden of Community‐Acquired Pneumonia in Seniors: Results of a Population‐Based Study. Clinical Infectious Diseases [Internet]. Oxford University Press (OUP); 2004 Dec;39(11):1642–50. Available from: https://doi.org/10.1086/425615

Howard LSGE, Sillis M, Pasteur MC, Kamath AV, Harrison BDW. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. Journal of Infection [Internet]. Elsevier BV; 2005 Feb;50(2):107–13. Available from: https://doi.org/10.1016/j.jinf.2004.05.003

Lieberman D, Schlaeffer F, Boldur I, Lieberman D, Horowitz S, Friedman MG, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax [Internet]. BMJ; 1996 Feb 1;51(2):179–84. Available from: https://doi.org/10.1136/thx.51.2.179

Kuzman I, Bezlepko A, Kondova Topuzovska I, Rókusz L, Iudina L, Marschall H-P, et al. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). BMC Pulmonary Medicine [Internet]. Springer Science and Business Media LLC; 2014 Jun 30;14(1). Available from: https://doi.org/10.1186/1471-2466-14-105

Karampela I, Dalamaga M. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? Archives of Medical Research [Internet]. Elsevier BV; 2020 Oct;51(7):741–2. Available from: https://doi.org/10.1016/j.arcmed.2020.06.004

Hooper DC. Mode of Action of Fluoroquinolones. Drugs [Internet]. Springer Science and Business Media LLC; 1999;58(Supplement 2):6–10. Available from: https://doi.org/10.2165/00003495-199958002-00002

Tano E, Cars O, Löwdin E. Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. Journal of Antimicrobial Chemotherapy [Internet]. Oxford University Press (OUP); 2005 May 26;56(1):240–2. Available from: https://doi.org/10.1093/jac/dki159

Pestova E. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. Journal of Antimicrobial Chemotherapy [Internet]. Oxford University Press (OUP); 2000 May 1;45(5):583–90. Available from: https://doi.org/10.1093/jac/45.5.583

Petitpretz P, Arvis P, Marel M, Moita J, Urueta J. Oral Moxifloxacin vs High-Dosage Amoxicillin in the Treatment of Mild-to-Moderate, Community-Acquired, Suspected Pneumococcal Pneumonia in Adults. Chest [Internet]. Elsevier BV; 2001 Jan;119(1):185–95. Available from: https://doi.org/10.1378/chest.119.1.185

Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy [Internet]. Oxford University Press (OUP); 1999 Dec;44(6):835–8. Available from: https://doi.org/10.1093/jac/44.6.835

Capitano B, Mattoes HM, Shore E, O’Brien A, Braman S, Sutherland C, et al. Steady-State Intrapulmonary Concentrations of Moxifloxacin, Levofloxacin, and Azithromycin in Older Adults. Chest [Internet]. Elsevier BV; 2004 Mar;125(3):965–73. Available from: https://doi.org/10.1378/chest.125.3.965

Breilh D, Jougon J, Djabarouti S, Gordien JB, Xuereb F, Velly JF, et al. Diffusion of Oral and Intravenous 400 mg Once-Daily Moxifloxacin into Lung Tissue at Pharmacokinetic Steady-State. Journal of Chemotherapy [Internet]. Informa UK Limited; 2003 Jan;15(6):558–62. Available from: https://doi.org/10.1179/joc.2003.15.6.558

Pea F, Pavan F, Lugatti E, Dolcet F, Talmassons G, Screm MC, et al. Pharmacokinetic and Pharmacodynamic Aspects of Oral Moxifloxacin 400 mg/day in Elderly Patients with Acute Exacerbation of Chronic Bronchitis. Clinical Pharmacokinetics [Internet]. Springer Science and Business Media LLC; 2006;45(3):287–95. Available from: https://doi.org/10.2165/00003088-200645030-00004

Barman Balfour JA, Lamb HM. Moxifloxacin. Drugs [Internet]. Springer Science and Business Media LLC; 2000 Jan;59(1):115–39. Available from: https://doi.org/10.2165/00003495-200059010-00010

Miravitlles M. Moxifloxacin in respiratory tract infections. Expert Opinion on Pharmacotherapy [Internet]. Informa Healthcare; 2005 Feb;6(2):283–93. Available from: https://doi.org/10.1517/14656566.6.2.283

Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: Cumulative data from clinical trials and postmarketing studies. Clinical Therapeutics [Internet]. Elsevier BV; 2004 Jul;26(7):940–50. Available from: https://doi.org/10.1016/s0149-2918(04)90170-1

Torres A, El-Ebiary M, Riquelme R, Ruiz M, Celis R. Community-acquired pneumonia in the elderly. InSeminars in respiratory infections 1999 Jun 1 (Vol. 14, No. 2, pp. 173-183).

Yakovlev SV. Moxifloxacin in severe community-acquired pneumonia: the first possibility of monotherapy. Pulmonology. 2002.

Finch R, Colins O, Kubin R, et al. Moxifloxacin IV/PO compared with amoxicillin/clavulanate IV/PO with or without clarithromycin in the treatment of community-acquired pneumonia. Clin Microbiol Infect 2001; 7 (Suppl 1): 167.

Drummond M, Finch R, Duprat-Lomon I, et al. Superior outcomes with moxifloxacin IV/PO monotherapy compared to IV/PO amoxicillin/clavulanate +/- clarithromycin in the treatment of community-acquired pneumonia [Poster 864]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 16-19 December, 2001.

Lemmen SW, Häfner H, Klik S, Lütticken R, Zolldann D. Comparison of the Bactericidal Activity of Moxifloxacin and Levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae. Chemotherapy [Internet]. S. Karger AG; 2003;49(1-2):33–5. Available from: https://doi.org/10.1159/000069779

Kuzman I, Bezlepko A, Kondova Topuzovska I, Rókusz L, Iudina L, Marschall H-P, et al. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). BMC Pulmonary Medicine [Internet]. Springer Science and Business Media LLC; 2014 Jun 30;14(1). Available from: https://doi.org/10.1186/1471-2466-14-105

Marciniec K, Beberok A, Pęcak P, Boryczka S, Wrześniok D. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis. Pharmacological Reports [Internet]. Springer Science and Business Media LLC; 2020 Oct 15;72(6):1553–61. Available from: https://doi.org/10.1007/s43440-020-00169-0

YU D, SUN S, LI Y, XI W, JIN D, SUN K, YU R, YAO X, SONG Z, YANG A, LUO R. Treatment with arbidol and moxifloxacin in ordinary and severe adult patients infected with COVID-19. MedRxiv. 2020 Jan 1.

Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases [Internet]. Oxford University Press (OUP); 2007 Mar 1;44(Supplement_2):S27–S72. Available from: https://doi.org/10.1086/511159

Alberta Health Services, CO. COVID-19 Scientific Advisory Group Rapid Response Report. 2020.

Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine [Internet]. Ovid Technologies (Wolters Kluwer Health); 2020 Mar 25;48(6):e440–e469. Available from: https://doi.org/10.1097/ccm.0000000000004363

Feshchenko YuI, Belosludtseva KO, Golubovska OA. Non-hospital pneumonia in adults: etiology, pathogenesis, classification, diagnostics, antibacterial therapy and prevention. The classic Nastanov was adapted, based on evidence. Standardized protocol for providing medical assistance, we grow up sick for non-hospital pneumonia: Official. K. Ukraine; 2016. 111 p.

Belforti RK, Lagu T, Haessler S, Lindenauer PK, Pekow PS, Priya A, et al. Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia. Clinical Infectious Diseases [Internet]. Oxford University Press (OUP); 2016 Apr 5;63(1):1–9. Available from: https://doi.org/10.1093/cid/ciw209

Fedorova OA. Moxifloxacin: pharmacoeconomic aspects of rational antibiotic therapy. Ukrainskyi medychnyi chasopys; 2014; 6:110-113.